Doruk Erkan, MD

Dr. Erkan received his medical degree at Hacettepe University School of Medicine in Ankara, Turkey. After his Internal Medicine residency at Beth Israel Medical Center in New York, he completed his Rheumatology fellowship at Hospital for Special Surgery in New York. Dr Erkan is an Assistant Attending Rheumatologist and Clinical Researcher at Hospital for Special Surgery and Assistant Professor of Medicine at Weill Medical College of Cornell University. He has a long-standing research interest in the field of autoimmune diseases, with particular focus on the antiphospholipid syndrome and lupus. Dr. Erkan has received several honors and awards from the American College of Rheumatology and the Arthritis Foundation for his research. He has published over 70 articles including research papers and invited editorials, as well as 15 book chapters, and he has given over 100 presentations. He is the co-editor of the Neurology volume of the Handbook of Systemic Autoimmune Disease and the Associate Editor of Hospital for Special Surgery’s Manual of Rheumatology and Outpatient Orthopedic Disorders.

Appointments

Assistant Attending Physician, Hospital for Special Surgery

Assistant Professor of Medicine, Weill Medical College of Cornell University

Associate Physician-Scientist, The Barbara Volcker Center for Women and Rheumatic Diseases

Specialty
Rheumatology

Certification

American Board of Rheumatology, 2001

Certificate in Clinical Epidemiology and Health Services Research, Weill Medical College of Cornell University, 2000

American Board of Internal Medicine, 1999

State Licensure
New York

Education

MD, Hacettepe University School of Medicine, Ankara, Turkey

Residency

Beth Israel Medical Center, New York, US

Doruk Erkan, MD is the author of the following articles on HSS.edu:

For Patients

• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• A Glimpse of Rheumatoid Arthritis Research at HSS

For Professionals

• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• CPC: Primary Antiphospholipid Syndrome Presenting as HELLP Syndrome
• CPC: Pulmonary Nodules in an Infliximab-Treated Rheumatoid Arthritis Patient
• CPC: An Unusual Case of Granulomatous Lung Disease

Special Expertise

Antiphospholipid syndrome

Systemic lupus erythematosus

Medical multimedia for physician and patient education

Awards

Young Investigator Initiative Award, US Bone and Joint Decade, 2006

Lupus Research Award, New York Community Trust, 2004

Dorothy W. Goldstein Young Scholar Award, Arthritis Foundation, New York Chapter, 2002

Rheumatology Fellow Award, American College of Rheumatology, 2001

Postdoctoral Fellowship Award, Arthritis Foundation, New York Chapter, 2001

Affiliations

American College of Rheumatology, Fellow

New York Rheumatism Association, Executive Committee

Selected Publications
For more publications, please see the PubMed listing.

Clinical Trials

• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 Week Study to Evaluate the Efficacy and Safety of Belimumab (GHS1006, LymphoStat-B), A fully Human monoclonal Anti-BlyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE).
• RITAPS: A Pilot Study Of Rituximab For The Anticoagulation-Resistant Manifestations Of Antiphospholipid Syndrome (APS)
• Pilot and Feasibility Study of Modafinil Treatment to Improve Cognitive Efficiency in SLE Patients
• LUNAR: A phase III, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of rituximab in subjects with class III or IV lupus nephritis
• EXPLORER: A randomized, double-blind, placebo controlled, multicenter, phase II/III study to evaluate the efficacy and safety of rituximab in subjects with moderate to severe systemic lupus erythematosus
• Autoimmune Disease Registry and Repository

Specialized Centers
Barbara Volcker Center for Women and Rheumatic Diseases